An amyloidogenic hexapeptide derived from amylin attenuates inflammation and acute lung injury in murine sepsis

Sidharth Mahapatra, Lihua Ying, Peggy Pui Kay Ho, Michael Kurnellas, Jonathan Rothbard, Lawrence Steinman, David N. Cornfield

Research output: Contribution to journalArticle

Abstract

Although the accumulation of amyloidogenic proteins in neuroinflammatory conditions is generally considered pathologic, in a murine model of multiple sclerosis, amyloid-forming fibrils, comprised of hexapeptides, are anti-inflammatory. Whether these molecules modulate systemic inflammatory conditions remains unknown. We hypothesized that an amylin hexapeptide that forms fibrils can attenuate the systemic inflammatory response in a murine model of sepsis. To test this hypothesis, mice were pre-treated with either vehicle or amylin hexapeptide (20 μg) at 12 hours and 6 hours prior to intraperitoneal (i.p.) lipopolysaccharide (LPS, 20 mg/kg) administration. Illness severity and survival were monitored every 6 hours for 3 days. Levels of pro- (IL-6, TNF-α, IFN-γ) and anti-inflammatory (IL-10) cytokines were measured via ELISA at 1, 3, 6, 12, and 24 hours after LPS (i.p.). As a metric of lung injury, pulmonary artery endothelial cell (PAEC) barrier function was tested 24 hours after LPS administration by comparing lung wet-to-dry ratios, Evan’s blue dye (EBD) extravasation, lung histology and caspase-3 activity. Compared to controls, pretreatment with amylin hexapeptide significantly reduced mortality (p<0.05 at 72 h), illness severity (p<0.05), and proinflammatory cytokine levels, while IL-10 levels were elevated (p<0.05). Amylin pretreatment attenuated LPS-induced lung injury, as demonstrated by decreased lung water and caspase-3 activity (p<0.05, versus PBS). Hence, in a murine model of systemic inflammation, pretreatment with amylin hexapeptide reduced mortality, disease severity, and preserved lung barrier function. Amylin hexapeptide may represent a novel therapeutic tool to mitigate sepsis severity and lung injury.

Original languageEnglish (US)
Article numbere0199206
JournalPloS one
Volume13
Issue number7
DOIs
StatePublished - Jul 2018

Fingerprint

Islet Amyloid Polypeptide
Acute Lung Injury
Sepsis
inflammation
lungs
Inflammation
mice
Lung Injury
pretreatment
animal models
Caspase 3
Interleukin-10
Lung
caspase-3
interleukin-10
Anti-Inflammatory Agents
Cytokines
cytokines
Amyloidogenic Proteins
Evans Blue

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Agricultural and Biological Sciences(all)

Cite this

Mahapatra, S., Ying, L., Ho, P. P. K., Kurnellas, M., Rothbard, J., Steinman, L., & Cornfield, D. N. (2018). An amyloidogenic hexapeptide derived from amylin attenuates inflammation and acute lung injury in murine sepsis. PloS one, 13(7), [e0199206]. https://doi.org/10.1371/journal.pone.0199206

An amyloidogenic hexapeptide derived from amylin attenuates inflammation and acute lung injury in murine sepsis. / Mahapatra, Sidharth; Ying, Lihua; Ho, Peggy Pui Kay; Kurnellas, Michael; Rothbard, Jonathan; Steinman, Lawrence; Cornfield, David N.

In: PloS one, Vol. 13, No. 7, e0199206, 07.2018.

Research output: Contribution to journalArticle

Mahapatra, Sidharth ; Ying, Lihua ; Ho, Peggy Pui Kay ; Kurnellas, Michael ; Rothbard, Jonathan ; Steinman, Lawrence ; Cornfield, David N. / An amyloidogenic hexapeptide derived from amylin attenuates inflammation and acute lung injury in murine sepsis. In: PloS one. 2018 ; Vol. 13, No. 7.
@article{fadbbac9729b415fa3bea7e667c0ba23,
title = "An amyloidogenic hexapeptide derived from amylin attenuates inflammation and acute lung injury in murine sepsis",
abstract = "Although the accumulation of amyloidogenic proteins in neuroinflammatory conditions is generally considered pathologic, in a murine model of multiple sclerosis, amyloid-forming fibrils, comprised of hexapeptides, are anti-inflammatory. Whether these molecules modulate systemic inflammatory conditions remains unknown. We hypothesized that an amylin hexapeptide that forms fibrils can attenuate the systemic inflammatory response in a murine model of sepsis. To test this hypothesis, mice were pre-treated with either vehicle or amylin hexapeptide (20 μg) at 12 hours and 6 hours prior to intraperitoneal (i.p.) lipopolysaccharide (LPS, 20 mg/kg) administration. Illness severity and survival were monitored every 6 hours for 3 days. Levels of pro- (IL-6, TNF-α, IFN-γ) and anti-inflammatory (IL-10) cytokines were measured via ELISA at 1, 3, 6, 12, and 24 hours after LPS (i.p.). As a metric of lung injury, pulmonary artery endothelial cell (PAEC) barrier function was tested 24 hours after LPS administration by comparing lung wet-to-dry ratios, Evan’s blue dye (EBD) extravasation, lung histology and caspase-3 activity. Compared to controls, pretreatment with amylin hexapeptide significantly reduced mortality (p<0.05 at 72 h), illness severity (p<0.05), and proinflammatory cytokine levels, while IL-10 levels were elevated (p<0.05). Amylin pretreatment attenuated LPS-induced lung injury, as demonstrated by decreased lung water and caspase-3 activity (p<0.05, versus PBS). Hence, in a murine model of systemic inflammation, pretreatment with amylin hexapeptide reduced mortality, disease severity, and preserved lung barrier function. Amylin hexapeptide may represent a novel therapeutic tool to mitigate sepsis severity and lung injury.",
author = "Sidharth Mahapatra and Lihua Ying and Ho, {Peggy Pui Kay} and Michael Kurnellas and Jonathan Rothbard and Lawrence Steinman and Cornfield, {David N.}",
year = "2018",
month = "7",
doi = "10.1371/journal.pone.0199206",
language = "English (US)",
volume = "13",
journal = "PLoS One",
issn = "1932-6203",
publisher = "Public Library of Science",
number = "7",

}

TY - JOUR

T1 - An amyloidogenic hexapeptide derived from amylin attenuates inflammation and acute lung injury in murine sepsis

AU - Mahapatra, Sidharth

AU - Ying, Lihua

AU - Ho, Peggy Pui Kay

AU - Kurnellas, Michael

AU - Rothbard, Jonathan

AU - Steinman, Lawrence

AU - Cornfield, David N.

PY - 2018/7

Y1 - 2018/7

N2 - Although the accumulation of amyloidogenic proteins in neuroinflammatory conditions is generally considered pathologic, in a murine model of multiple sclerosis, amyloid-forming fibrils, comprised of hexapeptides, are anti-inflammatory. Whether these molecules modulate systemic inflammatory conditions remains unknown. We hypothesized that an amylin hexapeptide that forms fibrils can attenuate the systemic inflammatory response in a murine model of sepsis. To test this hypothesis, mice were pre-treated with either vehicle or amylin hexapeptide (20 μg) at 12 hours and 6 hours prior to intraperitoneal (i.p.) lipopolysaccharide (LPS, 20 mg/kg) administration. Illness severity and survival were monitored every 6 hours for 3 days. Levels of pro- (IL-6, TNF-α, IFN-γ) and anti-inflammatory (IL-10) cytokines were measured via ELISA at 1, 3, 6, 12, and 24 hours after LPS (i.p.). As a metric of lung injury, pulmonary artery endothelial cell (PAEC) barrier function was tested 24 hours after LPS administration by comparing lung wet-to-dry ratios, Evan’s blue dye (EBD) extravasation, lung histology and caspase-3 activity. Compared to controls, pretreatment with amylin hexapeptide significantly reduced mortality (p<0.05 at 72 h), illness severity (p<0.05), and proinflammatory cytokine levels, while IL-10 levels were elevated (p<0.05). Amylin pretreatment attenuated LPS-induced lung injury, as demonstrated by decreased lung water and caspase-3 activity (p<0.05, versus PBS). Hence, in a murine model of systemic inflammation, pretreatment with amylin hexapeptide reduced mortality, disease severity, and preserved lung barrier function. Amylin hexapeptide may represent a novel therapeutic tool to mitigate sepsis severity and lung injury.

AB - Although the accumulation of amyloidogenic proteins in neuroinflammatory conditions is generally considered pathologic, in a murine model of multiple sclerosis, amyloid-forming fibrils, comprised of hexapeptides, are anti-inflammatory. Whether these molecules modulate systemic inflammatory conditions remains unknown. We hypothesized that an amylin hexapeptide that forms fibrils can attenuate the systemic inflammatory response in a murine model of sepsis. To test this hypothesis, mice were pre-treated with either vehicle or amylin hexapeptide (20 μg) at 12 hours and 6 hours prior to intraperitoneal (i.p.) lipopolysaccharide (LPS, 20 mg/kg) administration. Illness severity and survival were monitored every 6 hours for 3 days. Levels of pro- (IL-6, TNF-α, IFN-γ) and anti-inflammatory (IL-10) cytokines were measured via ELISA at 1, 3, 6, 12, and 24 hours after LPS (i.p.). As a metric of lung injury, pulmonary artery endothelial cell (PAEC) barrier function was tested 24 hours after LPS administration by comparing lung wet-to-dry ratios, Evan’s blue dye (EBD) extravasation, lung histology and caspase-3 activity. Compared to controls, pretreatment with amylin hexapeptide significantly reduced mortality (p<0.05 at 72 h), illness severity (p<0.05), and proinflammatory cytokine levels, while IL-10 levels were elevated (p<0.05). Amylin pretreatment attenuated LPS-induced lung injury, as demonstrated by decreased lung water and caspase-3 activity (p<0.05, versus PBS). Hence, in a murine model of systemic inflammation, pretreatment with amylin hexapeptide reduced mortality, disease severity, and preserved lung barrier function. Amylin hexapeptide may represent a novel therapeutic tool to mitigate sepsis severity and lung injury.

UR - http://www.scopus.com/inward/record.url?scp=85049649641&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85049649641&partnerID=8YFLogxK

U2 - 10.1371/journal.pone.0199206

DO - 10.1371/journal.pone.0199206

M3 - Article

C2 - 29990318

AN - SCOPUS:85049649641

VL - 13

JO - PLoS One

JF - PLoS One

SN - 1932-6203

IS - 7

M1 - e0199206

ER -